EU103 / Eutilex - LARVOL DELTA

Eutilex, JP Morgan Bio Partnering Consults with 10 Global Innovative Technology Companies [Google translation] (BioTimes) - "Eutilex announced on the 22nd that it had held meetings with about 10 global innovative technology companies and investment-related companies from the US and Switzerland regarding the GPC3 target solid cancer CAR-T treatment 'EU307' and the VSIG4 target antibody treatment 'EU103'...Yutilex plans to accelerate the advancement of its ‘Armored CAR-T platform’ through cutting-edge technology collaboration with them...Yutilex also met with Professor Carl June of the University of Pennsylvania, who attended the forum event held during JP Morgan Week, and discussed the positive effect of its EU307 in the clinical trial of GPC3-expressing advanced hepatocellular carcinoma through Armoring IL-18."

Clinical • Hepatocellular Cancer

A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Eutilex | Not yet recruiting ➔ Recruiting | Trial completion date: May 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Apr 2025

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Eutilex completes registration of Chinese patent for antibody therapy 103 [Google translation] (HIT News) - "Eutilex...announced on the 8th that it has completed the Chinese patent registration for antibody treatment 103...103, a dual-function antibody treatment that targets macrophages and killer T cells simultaneously, blocks immunosuppressive macrophages (M2) from suppressing T cells in the tumor microenvironment (TME)....'We are also focusing on our patent strategy, including actively securing exclusive and exclusive rights in major countries.'"

Patent • Oncology • Solid Tumor

Anti-cancer activities of EU103 in a preclinical model of ovarian cancer (SITC 2023) - "In the United States alone, we expect approximately 20,000 new diagnoses and more than 12,000 deaths for this year. Given our findings in this study and clinical significance, we propose here the therapeutic potential of EU103, previously developed by our proprietary antibody discovery and engineering technology, in ovarian cancer."

IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Gastric Cancer • Gastrointestinal Cancer • Glioma • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD34 • CD8 • CTLA4 • PD-L1

EU-103 demonstrates efficacy in preclinical models of ovarian cancer (Bioworld) - "Researchers from Eutilex Co. Ltd. have presented preclinical data for the novel V-set and immunoglobulin domain-containing 4 (VSIG4)-specific humanized monoclonal antibody, EU-103, being developed as a potential cancer immunotherapy candidate."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer. (ASCO 2023) - " Expanding our previous findings with the therapeutic potential of EU103 in a non-small cell lung carcinoma (NSCLC), here, we also proved its therapeutic effect in human ovarian cancer. Almost 300,000 women are diagnosed with ovarian cancer worldwide each year, and ovarian cancer ranks fifth in cancer deaths among women. In the United States alone, we expect approximately 20,000 new diagnoses and more than 12,000 deaths for this year. Given our findings in this study and clinical significance, we propose here the therapeutic potential of EU103, previously developed by our proprietary antibody discovery and engineering technology, in ovarian cancer."

IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Gastric Cancer • Gastrointestinal Cancer • Glioma • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD34 • CD8 • CTLA4 • PD-L1

A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Eutilex

Metastases • New P1 trial • Oncology • Solid Tumor

Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment. (SITC 2022) - "Since the main cause of Immune Checkpoint Inhibitor (ICI) resistance is an immune-suppressive TME, EU103 could be an option for ICI-resistant patients, and synergistic anti-tumor effect could be expected with a combination with ICIs. Overall, targeting the VSIG4 would be an advantageous approach in cancer therapeutics."

Biomarker • Combination therapy • IO biomarker • Tumor microenvironment • Lung Cancer • Oncology • Solid Tumor • CD14 • CD163 • CD40 • CD8 • CD86 • CSF1R • CTLA4 • IFNG • PTPRC

Eutilex, ’EU103’ Nonclinical Data SITC Abstract Adoption (Eutilex Press Release) - "Eutilex...will present the research results of the antibody treatment 'EU103' at the Society for Immunotherapy of Cancer (SITC) to be held in November. According to the company, the subject of EU103 research abstract adopted at this SITC is 'Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth in the tumor microenvironment. of tumor via conditioning of tumor microenvironment)....The company plans to explain the increased anticancer effect when combined with an immune checkpoint inhibitor, which is leading the existing immuno-oncology market, at the SITC to be held in November."

Preclinical • Oncology